Multiomic Health
multiomic.health
Actively hiring
Health Care
Precision Medicine
As featured in
Follow
Overview
News
Salaries
Products
People
Growth
Offices
Financials
Funding and backers
Total raised
$6.2M
1 round on record
Latest round
$6.2M
Seed · May 2023 · 3 yr ago
Team
11-50
employees, estimated range
Backers
2
Hoxton Ventures, MMC
The money's age
Long since its last round
40 months since the last round · not hiring
Momentum
15/100
in the news
Last sign of life
this month
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Sep 22
Partnership MultiOmic Health and Mesh Bio Partner to Use AI to Develop Precision Medicines and Diagnostics for Chronic Metabolic Disease · multiomic.health
Sep 4, 2025
Partnership MultiOmic Health and BIO4 Campus Sign MoU to Advance Precision Medicine and Support Bioeconomy Growth in Serbia · multiomic.health
Apr 2, 2025
Partnership MultiOmic Health and Alloy Therapeutics Collaborate to Discover and Develop Renal Tissue-Targeting Drugs · multiomic.health
Feb 7, 2024
Partnership MultiOmic Health and Queen's University Belfast join forces to transform diabetic kidney disease diagnosis · multiomic.health
May 4, 2023
Raised a round Seed $6.2M · businesswire
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Seed | May 2023 | $6.2M | — | businesswire |
Registers and programsofficial lists and records that name the company
| Legal entity | Multiomic Health Limited | its site |
Backed byfrom the funds' portfolios and accelerator catalogs
Hoxton Ventures 
MMC Similar startupsby what they do, their industry and backers
Sano’s end-to-end precision medicine platform de-risks trials, enabling clinical operations teams to move 10x faster and reduce cost by 5x.
Cellply offers an automated platform for functional precision medicine.
About UsGET TO KNOWOur Founders The medical potential of AI and metabolite Dr. Leila Pirhajico-founderOn Beyond Genome: Opportunities and…
Precision oncology, built for Latin America. Point-of-care software and a multimodal cancer atlas.
Genialis is a precision oncology company helping the most promising molecules become life-saving medicines.
Founded in 2021 by four Seoul National University medical researchers, Portrai fuses spatial biology and AI to make drug development…
News
Privacy Notice.
PRIVACY NOTICE & COOKIE POLICY who we are MultiOmic Health Limited, a private limited company registered in England and Wales (CRN: 13246608). Our registered office is located at Epworth House, 25 City Road, Shoreditch, London, EC1Y 1AA. We are a computat
Read more
Report
Leveraging deep omics data to tackle a global health challenge with precision
We are excited to announce our feature in the most recent edition of Nature Portfolio's Biopharma Dealmakers discussing the advances in AI-driven drug development.
Read more
Report
Understanding the AI-enabled Drug Discovery Landscape
An Expert View from Henrietta Bull, science and partnership analyst, and Robert Thong, chief executive, MultiOmic Health.
Read more
Report
Leveraging AI to Tackle the Looming Metabolic Syndrome Crisis
In this article, we look at how Mesh Bio and MultiOmic Health use AI to transform and improve the lives of metabolic syndrome patients through patient stratification and precision medicine.
Read more
Report
MultiOmic Health and Mesh Bio Partner to Use AI to Develop Precision Medicines and Diagnostics for Chronic Metabolic Disease
MultiOmic Health and Mesh Bio announce their partnership to conduct an observational clinical study on patients with chronic metabolic disease.
Read more
Report
The Pharma Letter Podcast - Episode 15 - Can AI find new drugs for metabolic diseases?
In this week's episode of The Pharma Letter Podcast, MultiOmic chief executive Robert Thong discusses his firm's progress and ambitions for the future.
Read more
Report
Honoured to be selected as winners of BIA's Innovation Showcase in the first ever TechBioUK conference
MultiOmic is proud to announce winning first place in the pitch competition at BIA's TechBio UK Conference 2022
Read more
Report
MultiOmic Health and BIO4 Campus Sign MoU to Advance Precision Medicine and Support Bioeconomy Growth in Serbia
MultiOmic Health and BIO4 Campus announced the signing of a Memorandum of Understanding (MoU) to explore collaborative opportunities in biomedicine, biotechnology, and bioinformatics, with a strong emphasis on artificial intelligence (AI) applications.
Read more
Report
Delivering precision medicines for chronic multifactorial diseases
MultiOmic Health is using a data-driven AI-enabled approach to develop tailored therapeutics for specific subpopulations of patients with metabolic syndrome-related conditions, which affect around half of the adult population worldwide.
Read more
Report
MultiOmic Health inks MoU with Alloy Therapeutics to discover and develop renal tissue-targeting drugs
MultiOmic Health inks MoU with Alloy Therapeutics to discover and develop renal tissue-targeting drugs
Read more
Report
Show more news
Offices
Where the company hires and what each office is for
Cities
1
Hiring now
0
Countries
1
London
United Kingdom
Registered seat
10-50 est. staff
Financials
Total raised
$6.2M
Latest round
Seed
Funding rounds
1
Funding rounds
| Round | Announced | Amount | |
|---|---|---|---|
| Seed | 2023 | $6.2M | Details |